Process optimization and synergistic anti-tumor effect of MET and CUR codelivery liposomes with improved drug encapsulation efficiency and stability

drug release experiments revealed a significant sustained-release characteristic of lip@MET/CUR. Specifically, the cumulative release rate of MET decreased from 96.8% to 57.4% within the initial 2 h. Results from MTT assays and experiments conducted in tumor-bearing mice further demonstrated that lip@MET/CUR was more effective in inhibiting the growth of HepG2 cells and tumors compared to free CUR or lip@CUR. In summary, our findings suggest that the optimized lip@MET/CUR formulation holds great potential as a candidate for investigating the synergistic effects of CUR and MET in tumor treatment.